Lercadip Adverse Reactions

Treatment with Lercadip is generally well tolerated. In controlled clinical trials, the most commonly observed side effects were related to the vasodilatory properties of lercanidipine: Flushing, peripheral edema, tachycardia, palpitation, headache, dizziness, asthenia. Other adverse experiences which were not clearly drug related and which occurred in <1% of patients were: Fatigue, gastrointestinal disturbances eg, dyspepsia, nausea, vomiting, epigastric pain and diarrhea, polyuria, rash, somnolence and myalgia.
Hypotension may occur in rare cases. Although not observed in clinical trials, gingival hyperplasia may rarely occur as reported following the use of other dihydropyridines. There were reports of isolated and reversible increases in serum levels of hepatic transaminases; no other clinically significant pattern of laboratory test abnormalities related to Lercadip has been observed. Lercadip does not appear to influence adversely blood sugar or serum lipid levels. Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very rarely patients with preexisting angina pectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardial infarction may be observed.